Urologix, Inc.
ULGX · OTC
3/31/2015 | 12/31/2014 | 9/30/2014 | 6/30/2014 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $4 |
| - Cash | $0 | $1 | $1 | $1 |
| + Debt | $5 | $5 | $5 | $5 |
| Enterprise Value | $6 | $6 | $7 | $8 |
| Revenue | $3 | $3 | $3 | $3 |
| % Growth | -9.2% | 1.9% | -8.3% | – |
| Gross Profit | $1 | $1 | $1 | $2 |
| % Margin | 46.9% | 47.5% | 48.4% | 48.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1.5% | -0.6% | -3.5% | -7.5% |
| Net Income | -$0 | -$0 | -$0 | -$4 |
| % Margin | -12.5% | -11.6% | -14.5% | -107% |
| EPS Diluted | -0.016 | -0.016 | -0.02 | -0.17 |
| % Growth | 2.4% | 19.2% | 88.1% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |